Cellistic Capacity Update May 2024: Cell & Gene Therapy

Cellistic specializes in process development and manufacture of immune cell therapies based on human induced pluripotent stem cell (iPSC) technology using their Pulse and Echo Platform. Our focus and expertise in iPSC reprogramming, gene editing, and differentiation development positions us to be the partner of choice for innovative cell therapy developers to advance into clinic. Leveraging more than a decade of scientific and technical knowledge and experience, Cellistic possesses unique capabilities for the design and optimization of proprietary manufacturing platforms for iPSC- based cell therapies.

Watch our presentation from the May 2024 OPCU event to examine the time saving factor of using Cellistic's predeveloped Pulse & Echo platforms, the IP considerations with iPCSs, and Cellistic's involvement in developing clinical therapies.